Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Featured News Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsBy Nathan Reiff. Publication Date: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Elon Musk already made me a "wealthy man"
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to grow to $366 billion over the next eight years. Companies often take a niche approach, developing medicines that target specific cancer types with dedicated mechanisms. Fortunately, a number of promising treatments have shown strong potential—and with that comes the possibility of significant sales. Two smaller biotech companies have seen notable share-price momentum thanks to their leading oncology medicines. Besides offering therapeutic potential, these drugs could help the firms move beyond penny-stock or otherwise unstable status and toward long-term profitability. In both cases, significant challenges remain, making these typical biotech investments high-risk but with the potential for outsized rewards. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle The Federal Reserve is selling banks their new FedNow system with one major promise: transfers will happen instantly, 24/7/365 with no more weekend or holiday delays—but when your money moves instantly through a centralized government hub, it can also be frozen instantly by automated algorithms inside the Fed's new network. Imagine it's 6:00 p.m. on a Friday when your account is instantly locked by a faceless government computer in Washington because an algorithm flagged a recent purchase or donation as suspicious, cutting you off from your own money until Monday morning or later with no way to pay for anything. Get the 4 steps to Fed-proof your savings now Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% in a week when the S&P 500 fell about 1%. That added to IOVA's year-to-date performance, during which shares have more than doubled. Still, with a consensus price target of $8.88, Wall Street is signaling additional upside—about 71% from current levels. The main catalyst for Iovance's move is Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi was approved in the U.S. for melanoma in 2024 and is gaining momentum, with rising sales and additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could reach more than $1 billion in U.S. peak sales. Amtagvi's potential extends beyond melanoma: it received FDA Fast Track designation for non-small cell lung cancer and may be effective against other cancer types. Iovance's outperformance was also supported by its Q4 2025 earnings report, issued in late February, where the company posted smaller-than-expected losses per share and $5 million in revenue. For the full year, revenue rose about 30% year over year. Iovance is a small, roughly $2 billion biotech and a penny stock. Despite the rally, analysts remain cautious: about half of its dozen ratings are Hold or Sell. Risks include the company's complex manufacturing process for Amtagvi—the therapy is personalized, costly, and difficult to produce, which could limit profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, but its year-to-date performance dwarfs Iovance's. IBRX shares are up nearly 300% in 2026 alone, and this could be just the beginning. Analysts have set a price target of $13.60, roughly 70% above the stock's current level even after the rally. ImmunityBio's lead product is Anktiva, a treatment for certain bladder cancers. In February, shares spiked after the E.U. regulator granted the drug conditional marketing authorization, the latest in a string of approvals worldwide. Anktiva helped drive revenue to $113 million last year—a roughly 700% year-over-year increase. Like Amtagvi, Anktiva may have potential against other cancer types, and ImmunityBio is exploring additional indications. Despite the surge over the last several quarters, IBRX shares remain speculative and risky. IBRX reported a full-year net loss of $351 million for 2025 as R&D expenses remain high. Wall Street analysts are relatively more bullish than for Iovance: six of seven rate the stock a Buy or equivalent. | 
